Humana Inc vs L3Harris Technologies Inc — how do they compare? Humana Inc trades at $442.02 (market cap $47.61B), while L3Harris Technologies Inc trades at $235.86 (market cap $43.51B). The key difference: Humana Inc and L3Harris Technologies Inc are close in size by market cap, and L3Harris Technologies Inc pays the higher dividend (2.14%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and L3Harris Technologies Inc for 55 Days on average.
| HUM | LHX | |
|---|---|---|
Market Cap | $47.61B | $43.51B |
Volume | 1,827,332 | 978,055 |
Sector | Health | Industrials |
52-Week High | $409.85 | $378.48 |
52-Week Low | $163.67 | $233.63 |
Typical Hold Time | 53 Days | 55 Days |
Enterprise Value | $54.97B | $53.95B |
Dividend Yield | 0.89% | 2.14% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
LHX trades at $236.92, down 0.41% with bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending. Recent contract wins include a $6 billion THAAD propulsion deal, while multiple law firms are investigating potential securities law violations. Operating cash flow improved to $3.11 billion in 2025, supporting a solid financial position.
Wall Street maintains strong bullish sentiment with 73% buy ratings and a $340 consensus target offering 44% upside. However, technical indicators show bearish momentum and legal investigations pose near-term risks. The defense sector benefits from robust government spending, but execution on major contracts and resolution of legal matters will drive future performance.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →